Does publication bias explain the divergent findings on menopausal hormone therapy and cardioprotection in the literature?

. 2021 May 4;5(4):e12515.

doi: 10.1002/rth2.12515. eCollection 2021 May.

Affiliations

¹ Department of Epidemiology Graduate School of Public Health University of Pittsburgh Pittsburgh PA USA.
² Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA USA.

Samar R El Khoudary et al. Res Pract Thromb Haemost. 2021.

. 2021 May 4;5(4):e12515.

doi: 10.1002/rth2.12515. eCollection 2021 May.

¹ Department of Epidemiology Graduate School of Public Health University of Pittsburgh Pittsburgh PA USA.
² Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA USA.

No abstract available

Keywords: cardioprotection; menopausal hormone therapy; menopause; publication bias; women's health.

References

1. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–e532. 10.1161/CIR.0000000000000912. - DOI - PubMed
1. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten‐year follow‐up from the nurses’ health study. N Engl J Med. 1991;325:756–762. - PubMed
1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47–63. - PubMed
1. American College of Physicians . Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117:1038–1041. - PubMed
1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. - PubMed